[go: up one dir, main page]

WO2025054631A3 - Compositions et procédés de régulation de populations bactériennes spécifiques - Google Patents

Compositions et procédés de régulation de populations bactériennes spécifiques Download PDF

Info

Publication number
WO2025054631A3
WO2025054631A3 PCT/US2024/046002 US2024046002W WO2025054631A3 WO 2025054631 A3 WO2025054631 A3 WO 2025054631A3 US 2024046002 W US2024046002 W US 2024046002W WO 2025054631 A3 WO2025054631 A3 WO 2025054631A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
control
bacterial populations
specific bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/046002
Other languages
English (en)
Other versions
WO2025054631A2 (fr
Inventor
Michael S. GILMORE
Ashlee EARL
Janira PRICHULA
Abigail MANSON
Gracie RICHARDS
Natia Karumidze
Francois LEBRETON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary, Broad Institute Inc filed Critical Massachusetts Eye and Ear Infirmary
Publication of WO2025054631A2 publication Critical patent/WO2025054631A2/fr
Publication of WO2025054631A3 publication Critical patent/WO2025054631A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un agent antimicrobien dérivé de phage de E. faecalis (éfagines). L'invention concerne également des compositions et des procédés d'utilisation des éfagines pour traiter des infections bactériennes.
PCT/US2024/046002 2023-09-10 2024-09-10 Compositions et procédés de régulation de populations bactériennes spécifiques Pending WO2025054631A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363537523P 2023-09-10 2023-09-10
US63/537,523 2023-09-10

Publications (2)

Publication Number Publication Date
WO2025054631A2 WO2025054631A2 (fr) 2025-03-13
WO2025054631A3 true WO2025054631A3 (fr) 2025-06-12

Family

ID=94924487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/046002 Pending WO2025054631A2 (fr) 2023-09-10 2024-09-10 Compositions et procédés de régulation de populations bactériennes spécifiques

Country Status (1)

Country Link
WO (1) WO2025054631A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210309703A1 (en) * 2020-04-07 2021-10-07 Pylum Biosciences, Inc. Enterocins and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210309703A1 (en) * 2020-04-07 2021-10-07 Pylum Biosciences, Inc. Enterocins and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 19 February 2014 (2014-02-19), "Enterococcus faecalis PF3 Phage protein sequence", Database accession no. V7ZNB4 *
KILJUNEN SAIJA, DATTA NEETA, DENTOVSKAYA SVETLANA V., ANISIMOV ANDREY P., KNIREL YURIY A., BENGOECHEA JOSé A., HOLST OTTO, SKURNI: "Identification of the Lipopolysaccharide Core of Yersinia pestis and Yersinia pseudotuberculosis as the Receptor for Bacteriophage φA1122", JOURNAL OF BACTERIOLOGY, vol. 193, no. 18, 15 September 2011 (2011-09-15), US , pages 4963 - 4972, XP093327288, ISSN: 0021-9193, DOI: 10.1128/JB.00339-11 *
TENG FANG, JACQUES-PALAZ KAREN D., WEINSTOCK GEORGE M., MURRAY BARBARA E.: "Evidence that the Enterococcal Polysaccharide Antigen Gene ( epa ) Cluster Is Widespread in Enterococcus faecalis and Influences Resistance to Phagocytic Killing of E. faecalis", INFECTION AND IMMUNITY, vol. 70, no. 4, 1 April 2002 (2002-04-01), US , pages 2010 - 2015, XP093327292, ISSN: 0019-9567, DOI: 10.1128/IAI.70.4.2010-2015.2002 *

Also Published As

Publication number Publication date
WO2025054631A2 (fr) 2025-03-13

Similar Documents

Publication Publication Date Title
WO2009111064A3 (fr) Composés de minocycline et procédés d’utilisation de ceux-ci
WO2007085852A3 (fr) Matieres antimicrobiennes
WO2007130655A3 (fr) Activités antimicrobiennes dérivées de bactériophages
AU2001278003A1 (en) Bacteriophage having multiple host range
CR20230012A (es) Composiciones y métodos para promover la salud de las plantas
NZ591051A (en) C7-fluoro substituted tetracycline compounds
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
MX393763B (es) Nanosistemas que comprenden plata y antibioticos y su uso para el tratamiento de infecciones bacterianas
MX2022000233A (es) Inhibidores de deteccion de quórum y/o metabolitos posbióticos y métodos relacionados.
WO2024076951A3 (fr) Promédicaments antiviraux et formulations correspondantes
WO2006120563A3 (fr) Agents antibacteriens
WO2025054631A3 (fr) Compositions et procédés de régulation de populations bactériennes spécifiques
MX344601B (es) Tratamiento de enfermedades asociadas con el uso de antibioticos.
EP2124976A4 (fr) Inhibition de la croissance et élimination de staphylococcus aureus résistant à la méthicilline par des bactéries d'acide lactique
WO2006107945A3 (fr) Utilisation de rip pour traiter des infections par staphylococcus aureus
WO2004034961A3 (fr) Antimicrobiens et leurs utilisations
EP4132539A4 (fr) Compositions et méthodes de traitement d'infections bactériennes
WO2018140707A8 (fr) Combinaison synergique de thermolysine et d'un agent antibactérien pour réduire ou éliminer les biofilms bactériens de surfaces
PH12021552875A1 (en) METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SpA) VARIANTS
WO2005113514A3 (fr) Pyrimidines substituees utilisees en tant qu'inhibiteurs de systemes bacteriens de secretion de proteine de type iii
WO2003101405A3 (fr) Antibiotiques a base d'amino-glycosides et procedes d'utilisation correspondants
WO2024030896A3 (fr) Compositions de bactériophages et méthodes de traitement d'infections bactériennes
PH12021550070A1 (en) Composition for inactivation of gram-positive bacteria and bacterial spores and mehtods of making and using same
WO2023003951A3 (fr) Compositions et méthodes pour le traitement d'une infection par le virus de l'herpès simplex
WO2024077093A3 (fr) Inhibiteurs de pbp4 de staphylococcus aureus et procédé d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24863806

Country of ref document: EP

Kind code of ref document: A2